ArticleFrontiers in immunology2022
Preoperative sarcopenia and systemic immune-inflammation index can predict response to intravesical Bacillus Calmette-Guerin instillation in patients with non-muscle invasive bladder cancer.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 5 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Prognostic and clinicopathological value of fibrinogen-to-albumin ratio in patients with esophageal cancer: a meta-analysis.World journal of surgical oncology · 2025Pooled it
- Prognostic value of the systemic immune-inflammation index in bladder cancer: an update evidence-based analysis.Frontiers in oncology · 2025Pooled it
- Prognostic significance of systemic immune inflammation index in patients with urothelial carcinoma: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- High systemic immune-inflammation index predicts poor prognosis and response to intravesical BCG treatment in patients with urothelial carcinoma: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Preoperative systemic immune-inflammation index as a prognostic indicator for patients with urothelial carcinoma.Frontiers in immunology · 2023Pooled it
- Cancer risk and mortality assessment in the overweight population: evaluation of single and integrated models based on inflammatory markers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Sarcopenia and recurrence risk in high-risk non-muscle-invasive bladder cancer: a nonlinear modeling approach.The journal of nutrition, health & aging · 2026Article
- Sarcopenia in Urothelial Bladder Carcinoma: A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- Construction of a column-line graphical model of poor outcome of neoadjuvant regimens for muscle-invasive bladder cancer based on NLR, dNLR and SII indicators.World journal of surgical oncology · 2025Article
- Sarcopenia and lower urinary tract diseases: links, mechanisms, and clinical implications.Frontiers in nutrition · 2025Review
- Development and external validation of a model to predict recurrence in patients with non-muscle invasive bladder cancer.Frontiers in immunology · 2024Article
- Advances in sarcopenia and urologic disorders.Frontiers in nutrition · 2024Review
- Predictive Significance of Systemic Immune-Inflammation Index in Patients with Breast Cancer: A Retrospective Cohort Study.OncoTargets and therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To explore the prognostic significance of sarcopenia and systemic immune-inflammation index (SII) for response to intravesical Bacillus Calmette-Guerin (BCG) in patients with intermediate-, and high-risk non-muscle invasive bladder cancer (NMIBC). Methods: We retrospectively analyzed 183 consecutive patients treated in Qilu hospital of Shandong University for a first diagnosis of intermediate and high risk NMIBC. Using computed tomography scans at the third lumbar vertebra level, we calculated skeletal muscle index (SMI). Sarcopenia was defined as SMI <43 cm Results: Compared with BCG responders, BCG non-responders were associated with sarcopenia (P < 0.001), carcinoma Conclusions: Both sarcopenia and high SII are useful predictors of response to intravesical BCG in intermediate- and high-risk NMIBC patients. Patients with intermediate- and high-risk NMIBC that had sarcopenia or high SII at diagnosis were associated with poor RFS, and the combination of sarcopenia and SII may be a better predictor of RFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.